Payment overview · 2025
General Payments
$1,313.20
10 reported records · 8 companies
Healthcare provider profile · identity verified
Efat Azizi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STATEN ISLAND, NY · NPI 1255580783
Verified facts
What the public records show
CMS Open Payments records show Efat Azizi, M.D. received $1,313.20 in general payments during 2025 across 10 reported records.
Gilead Sciences, Inc. accounted for 42.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kisqali.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KISQALI as an associated drug or biological on 31637 records involving 7959 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kisqali by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $555.56 | 42.3% | 2 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $271.49 | 20.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $125.00 | 9.5% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $119.12 | 9.1% | 1 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $106.14 | 8.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.49 | 5.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.74 | 3.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.66 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $535.35 | 7 |
| Consulting Fee | $450.00 | 1 |
| Honoraria | $259.36 | 1 |
| Education | $68.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $555.56 | 2 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $271.49 | 2 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $119.12 | 1 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $106.14 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $68.49 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $44.74 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $22.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| KISQALI kisqali |
2025 | Kisqali | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | KISQALI open payments reported associated product |
CMS Open Payments — General Payments 31637 supporting records · 7959 recipient NPIs · example record 1200004789 |
Kisqali · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 203 | 77 |
| Xtandi | Enzalutamide | 105 | 20 |
| Aranesp | Darbepoetin Alfa In Polysorbat | 89 | 34 |
| Xgeva | Denosumab | 54 | 17 |
| Lupron Depot | Leuprolide Acetate | 52 | 21 |
| Darzalex Faspro | Daratumumab-Hyaluronidase-Fihj | 51 | suppressed |
| Prednisone | Prednisone | 51 | 14 |
| Abiraterone Acetate | Abiraterone Acetate | 46 | suppressed |
| Hydroxyurea | Hydroxyurea | 42 | 13 |
| Revlimid | Lenalidomide | 38 | suppressed |
| Akynzeo | Fosnetupitant/Palonosetron | 37 | 11 |
| Eliquis | Apixaban | 37 | 15 |
| Procrit | Epoetin Alfa | 33 | 15 |
| Neulasta Onpro | Pegfilgrastim | 31 | suppressed |
| Brukinsa | Zanubrutinib | 28 | suppressed |
| Letrozole | Letrozole | 28 | suppressed |
| Exemestane | Exemestane | 26 | suppressed |
| Verzenio | Abemaciclib | 25 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Orencia | Abatacept/Maltose | 21 | suppressed |
| Folic Acid | Folic Acid | 19 | 13 |
| Kisqali | Ribociclib Succinate | 18 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Gabapentin | Gabapentin | 17 | suppressed |
| Lenalidomide | Lenalidomide | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 13 |
| Bortezomib | Bortezomib | 11 | suppressed |
| Imbruvica | Ibrutinib | 11 | suppressed |
| Jevtana | Cabazitaxel | 11 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 11 | suppressed |
| Zoledronic Acid | Zoledronic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,313.20 · 10 records | Gilead Sciences, Inc. | IMFINZI, JEMPERLI, KEYTRUDA, KISQALI, Optune Lua (NovoTTF-200T), SARCLISA, Trodelvy, XPOVIO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kisqali play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error